| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Salk Institute for Biological Studies, Regulatory Biology Laboratory, San Diego, California 92186-5800
P-Glycoproteins represent a family of drug efflux proteins that convey multidrug resistance to cells in which they are expressed. This phenomenon can lower the efficacy of drugs used in chemotherapy. The steroid progesterone has been shown to bind P-glycoproteins and inhibit their drug efflux. We report that the antiprogestin RU 486 can reverse multidrug resistance in cells overexpressing the mouse mdr1 gene. Using flow cytometry to measure inhibition of P-glycoprotein-dependent efflux of rhodamine 123, RU 486 was found to be considerably more effective than progesterone and one-half as effective as verapamil. The results suggest a valuable new use for RU 486.
1 This work was supported by Core Grant CA-14195 from the National Cancer Institute and grants from the American Cancer Society and the Elsa U. Pardee Foundation (to S. B.).
2 To whom requests for reprints should be addressed, at The Salk Institute for Biological Studies, P.O. Box 85800, San Diego, CA 92186-5800.
Received 1/28/94. Accepted 5/ 4/94.
This article has been cited by other articles:
|
|
 |
|
  B. T. MOE, A. B. VEREIDE, A. oRBO, R. JAeGER, and G. SAGER Levonorgestrel, Medroxyprogesterone and Progesterone Cause a Concentration-dependent Reduction in Endometrial Cancer (Ishikawa) Cell Density, and High Concentrations of Progesterone and Mifepristone Act in Synergy Anticancer Res, April 1, 2009; 29(4): 1047 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Woodland, G. Koren, and S. Ito From Bench to Bedside: Utilization of an In Vitro Model to Predict Potential Drug-Drug Interactions in the Kidney: The Digoxin-Mifepristone Example J. Clin. Pharmacol., July 1, 2003; 43(7): 743 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gruol, M. N. King, and M. E. Kuehne Evidence for the Locations of Distinct Steroid and Vinca Alkaloid Interaction Domains within the Murine mdr1b P-Glycoprotein Mol. Pharmacol., November 1, 2002; 62(5): 1238 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Khan, Y. Q. He, M. A. Correia, and J. R. Halpert Differential Oxidation of Mifepristone by Cytochromes P450 3A4 and 3A5: Selective Inactivation of P450 3A4 Drug Metab. Dispos., September 1, 2002; 30(9): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. D. Vo and D. J. Gruol Identification of P-glycoprotein Mutations Causing a Loss of Steroid Recognition and Transport J. Biol. Chem., July 16, 1999; 274(29): 20318 - 20327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. He, T. F. Woolf, and P. F. Hollenberg Mechanism-Based Inactivation of Cytochrome P-450-3A4 by Mifepristone (RU486) J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 791 - 797. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Conseil, H. Baubichon-Cortay, G. Dayan, J.-M. Jault, D. Barron, and A. Di Pietro Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein PNAS, August 18, 1998; 95(17): 9831 - 9836. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
